As of June 12, 2025, Novo Integrated Sciences Inc (NVOS) reports a Net Margin of -121.61%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Novo Integrated Sciences Inc's Net Margin
Over recent years, Novo Integrated Sciences Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-08-31 | -121.61% |
| 2023-08-31 | -105.11% |
| 2022-08-31 | -279.81% |
| 2021-08-31 | -47.91% |
| 2020-08-31 | -62.60% |
This slight downward trend highlights how Novo Integrated Sciences Inc manages its overall profitability and cost control over time.
Comparing Novo Integrated Sciences Inc's Net Margin to Peers
To better understand Novo Integrated Sciences Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Novo Integrated Sciences Inc (NVOS) | -121.61% |
| Global Cord Blood Corp (CO) | 40.30% |
| Avem Health Partners Inc (FPCG) | 29.77% |
| PharmChem Inc (PCHM) | 22.69% |
| Interpace Biosciences Inc (IDXG) | 14.28% |
| Quest Diagnostics Inc (DGX) | 8.82% |
Compared to its competitors, Novo Integrated Sciences Inc's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.